ArticleBMC infectious diseases2025
Low-level viremia and subsequent virologic failure among people living with HIV: a retrospective cohort study in China.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Concomitant cytomegalovirus DNAemia is associated with sustained TNF-α elevation in HIV/AIDS: a multivariable and longitudinal analysis of immune restoration.BMC infectious diseases · 2026Observational
- Maintain, not obtain: rethinking HIV care in sub-Saharan Africa in the era of dolutegravir.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundUnderstanding the current status of low-level viremia (LLV) is necessary for controlling the spread of HIV globally. However, the existing data on LLV prevalence during antiretroviral therapy (ART) and LLV risk contributing to subsequent virologic failure (VF) is still scant in China.
methodsA large sample size, retrospective cohort study was conducted in Hubei province, China between January 1, 2011 and October 30, 2023. The LLV incidence was evaluated according to the first viral load of each year. The risk factors associated with LLV and subsequent VF among people living with HIV (PLWH) were accessed.
resultsTotally, 25,607 PLWH managed by Hubei province Center for Disease Control and Prevention were screened, and 19,930 PLWH were eligible for the study. Of them, 18,052 received the first line ART, 1103 received the second line ART, and 963 received the third line ART. 2497 (13.8%) PLWH on first line, 189 (17.1%) PLWH on second line and 100 (10.4%) PLWH on third line ART experienced LLV, respectively.The LLV level between 51 and 199 copies/ml was the most common in both three groups. CD4 count < 200 cells/µL and older age at ART initiation were associated with higher risk of LLV among all PLWH and PLWH receiving the first line ART, and protease inhibitors (PIs) using was associated with the higher risk of LLV among all PLWH. Both LLV level among 51-199, 200-399 and 400-999 copies/mL were risk factors leading to VF occurrence.
conclusionsClose surveillance of HIV-VL is imperative among PLWH with CD4 count < 200 cells/µL, older age and PIs use for avoiding LLV occurrence. Clinical strategies should be strengthened among PLWH with LLV, given the increased vulnerability to subsequent VF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.